Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats

References

• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588-98; PMID:19196675; http://dx.doi.org/10.1056/NEJMoa0804877
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55; PMID:20399493; http://dx.doi.org/10.1016/S0140-6736(10)60206-1
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31:5-9; PMID:21817948; http://dx.doi.org/10.1097/INF.0b013e31822e68e6
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199-203; PMID:3399292
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59; PMID:15858184; http://dx.doi.org/10.1056/NEJMoa043951
   PubMed Web of Science ®Google Scholar
• Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162:80-99; PMID:21963675; http://dx.doi.org/10.1016/j.virusres.2011.09.020
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 2008; 121:235-43; PMID:18245413; http://dx.doi.org/10.1542/peds.2007-1102
   PubMed Web of Science ®Google Scholar
• Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000; 137:78-84; PMID:10891826; http://dx.doi.org/10.1067/mpd.2000.105350
   PubMed Web of Science ®Google Scholar
• Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 2008; 7:249-58; PMID:18324893; http://dx.doi.org/10.1586/14760584.7.2.249
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-63; PMID:4305200
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-48; PMID:4305199
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21; PMID:4305197
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34; PMID:4305198
   PubMed Web of Science ®Google Scholar
• Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996; 70:2852-60; PMID:8627759
   PubMed Web of Science ®Google Scholar
• Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999; 73:8485-95; PMID:10482601
   PubMed Web of Science ®Google Scholar
• Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994; 68:5321-5; PMID:8035532
   PubMed Web of Science ®Google Scholar
• Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 2003; 77:9831-44; PMID:12941892; http://dx.doi.org/10.1128/JVI.77.18.9831-9844.2003
   PubMed Web of Science ®Google Scholar
• Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC 3rd, Sotnikov AV, Murphy BR. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 1992; 66:7444-51; PMID:1433525
   PubMed Web of Science ®Google Scholar
• Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032-40; PMID:8345194
   PubMed Web of Science ®Google Scholar
• Johnson TR, Teng MN, Collins PL, Graham BS. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 2004; 78:6024-32; PMID:15141000; http://dx.doi.org/10.1128/JVI.78.11.6024-6032.2004
   PubMed Web of Science ®Google Scholar
• Cherukuri A, Stokes KL, Patton K, Kuo H, Sakamoto K, Lambert S, Stillman E, Moore ML, Lee S. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing 2012; 9:21; PMID:23031690; http://dx.doi.org/10.1186/1742-4933-9-21
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004; 21:1519-30; PMID:15497674; http://dx.doi.org/10.1023/B:PHAM.0000041443.17935.33
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007; 75:4020-9; PMID:17502384; http://dx.doi.org/10.1128/IAI.00070-07
   PubMed Web of Science ®Google Scholar
• Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954; PMID:18698426; http://dx.doi.org/10.1371/journal.pone.0002954
   PubMed Web of Science ®Google Scholar
• Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young KS, et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003; 21:3801-14; PMID:12922114; http://dx.doi.org/10.1016/S0264-410X(03)00381-5
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 2012; 30:307-16; PMID:22079079; http://dx.doi.org/10.1016/j.vaccine.2011.10.094
   PubMed Web of Science ®Google Scholar
• Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012; 30:6871-7; PMID:22989689; http://dx.doi.org/10.1016/j.vaccine.2012.09.007
   PubMed Web of Science ®Google Scholar
• Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr, Lukacs NW. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One 2011; 6:e21823; PMID:21789184; http://dx.doi.org/10.1371/journal.pone.0021823
   PubMed Web of Science ®Google Scholar
• Passmore C, Makidon PE, O'Konek JJ, Zahn JA, Pannu J, Hamouda T, Bitko V, Myc A, Lukacs NW, Fattom A, et al. Intranasal immunization with W 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model. Hum Vaccin Immunother 2013; 10; 615-22; PMID:24326268
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, Baker JR Jr. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008; 15:348-58; PMID:18057181; http://dx.doi.org/10.1128/CVI.00440-07
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Gerber M, Blanco LP, Makidon PE, Janczak KW, Beer M, Swanson B, Baker JR Jr. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol 2010; 30:189-99; PMID:20370629; http://dx.doi.org/10.1615/CritRevImmunol.v30.i2.60
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR, Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008; 24:271-81; PMID:18260780; http://dx.doi.org/10.1089/aid.2007.0148
   PubMed Web of Science ®Google Scholar
• Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker JR. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010; 6:585-94; PMID:20421727; http://dx.doi.org/10.4161/hv.6.7.11818
   PubMed Web of Science ®Google Scholar
• Hamouda T, Sutcliffe JA, Ciotti S, Baker JR, Jr. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin Vaccine Immunol 2011; 18:1167-75; PMID:21543588; http://dx.doi.org/10.1128/CVI.00035-11
   PubMed Web of Science ®Google Scholar
• Makidon PE, Nigavekar SS, Bielinska AU, Mank N, Shetty AM, Suman J, Knowlton J, Myc A, Rook T, Baker JR, Jr. Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J Aerosol Med Pulm Drug Deliv 2010; 23:77-89; PMID:19778268; http://dx.doi.org/10.1089/jamp.2009.0766
   PubMed Web of Science ®Google Scholar
• Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978; 93:771-91; PMID:362946
   PubMed Web of Science ®Google Scholar
• Niewiesk S, Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 2002; 36:357-72; PMID:12396279; http://dx.doi.org/10.1258/002367702320389026
   PubMed Web of Science ®Google Scholar
• Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 1986; 57:721-8; PMID:2419587
   PubMed Web of Science ®Google Scholar
• Wong PT, Leroueil PR, Smith DM, Ciotti S, Bielinska AU, Janczak KW, Mullen CH, Groom JV 2nd, Taylor EM, Passmore C, et al. Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. PLoS One 2015; 10:e0126120; PMID:25962136; http://dx.doi.org/10.1371/journal.pone.0126120
   PubMed Web of Science ®Google Scholar
• Wong PT, Wang SH, Ciotti S, Makidon PE, Smith DM, Fan Y, Schuler CFt, Baker JR Jr. Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity. Mol Pharm 2014; 11:531-44; PMID:24320221; http://dx.doi.org/10.1021/mp4005029
   PubMed Web of Science ®Google Scholar
• Kim CK, Lee SW, Choi HG, Lee MK, Gao ZG, Kim IS, Park KM. Trials of in situ gelling and mucoadhesive acetaminophen liquid suppository in human subjects. Int J Pharm 1998; 174:201-7; http://dx.doi.org/10.1016/S0378-5173(98)00258-0
   Web of Science ®Google Scholar
• Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151:34-42, e1; PMID:17586188; http://dx.doi.org/10.1016/j.jpeds.2007.02.032
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329:1524-30; PMID:8413475; http://dx.doi.org/10.1056/NEJM199311183292102
   PubMed Web of Science ®Google Scholar
• Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985; 55:517-20; PMID:4020957
   PubMed Web of Science ®Google Scholar
• Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41; PMID:19079256; http://dx.doi.org/10.1038/nm.1894
   PubMed Web of Science ®Google Scholar
• Loebbermann J, Durant L, Thornton H, Johansson C, Openshaw PJ. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci U S A 2013; 110:2987-92; PMID:23382205; http://dx.doi.org/10.1073/pnas.1217580110
   PubMed Web of Science ®Google Scholar
• Shaw CA, Galarneau JR, Bowenkamp KE, Swanson KA, Palmer GA, Palladino G, Markovits JE, Valiante NM, Dormitzer PR, Otten GR. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease. Vaccine 2013; 31:306-12; PMID:23153444; http://dx.doi.org/10.1016/j.vaccine.2012.11.006
   PubMed Web of Science ®Google Scholar
• Makidon PE, Belyakov IM, Blanco LP, Janczak KW, Landers J, Bielinska AU, Groom JV, 2nd, Baker JR, Jr. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur J Immunol 2012; 42:2073-86; PMID:22653620; http://dx.doi.org/10.1002/eji.201142346
   PubMed Web of Science ®Google Scholar
• Wang SH, Fan Y, Makidon PE, Cao Z, Baker JR. Induction of immune tolerance in mice with a novel mucosal nanoemulsion adjuvant and self-antigen. Nanomedicine (Lond) 2012; 7:867-76; PMID:22420425; http://dx.doi.org/10.2217/nnm.11.187
   PubMed Web of Science ®Google Scholar
• Herlocher ML, Ewasyshyn M, Sambhara S, Gharaee-Kermani M, Cho D, Lai J, Klein M, Maassab HF. Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine. Vaccine 1999; 17:172-81; PMID:9987152; http://dx.doi.org/10.1016/S0264-410X(98)00155-8
   PubMed Web of Science ®Google Scholar
• Ueba O. Respiratory syncytial virus. I. Concentration and purification of the infectious virus. Acta Med Okayama 1978; 32:265-72; PMID:153087
   PubMed Web of Science ®Google Scholar